Marks Michael P, Lansberg Maarten G, Mlynash Michael, Kemp Stephanie, McTaggart Ryan A, Zaharchuk Greg, Bammer Roland, Albers Gregory W
Stanford Stroke Center, Stanford University School of Medicine, Palo Alto, CA, USA.
Int J Stroke. 2014 Oct;9(7):860-5. doi: 10.1111/ijs.12271. Epub 2014 Mar 31.
DEFUSE 2 demonstrated that patients with magnetic resonance imaging mismatch had a favorable clinical response to tissue reperfusion assessed by magnetic resonance imaging. This study reports the endovascular results and correlates angiographic reperfusion with clinical and imaging outcomes.
Prospectively enrolled ischemic stroke patients underwent baseline magnetic resonance imaging and started endovascular therapy within 12 h of onset. Patients were classified as either target mismatch or no target mismatch using magnetic resonance imaging. The pre- and postprocedure angiogram was evaluated to determine thrombolysis in cerebral infarction scores. Favorable clinical response was determined at day 30, and good functional outcome was defined as a modified Rankin Scale 0-2 at day 90.
One-hundred patients had attempted endovascular treatment. At procedure end, 23% were thrombolysis in cerebral infarction 0-1, 31% thrombolysis in cerebral infarction 2A, 28% thrombolysis in cerebral infarction 2B, and 18% thrombolysis in cerebral infarction 3. More favorable thrombolysis in cerebral infarction-reperfusion scores were associated with greater magnetic resonance imaging reperfusion (P<0·001). thrombolysis in cerebral infarction scores correlated with 30-day favorable clinical response (P=0·041) and 90-day modified Rankin Scale 0-2 (P=0·008). These correlations were significant for target mismatch patients at 30 days (P=0·034) and 90 days (P=0·003). Infarct growth was strongly associated with poorer thrombolysis in cerebral infarction scores in target mismatch patients (P<0·001). Patients with thrombolysis in cerebral infarctionnfarction 2A reperfusion had less magnetic resonance imaging reperfusion (P=0·004) and poorer clinical outcome at 90 days (P=0·01) compared with thrombolysis in cerebral infarction 2B-3 patients.
Thrombolysis in cerebral infarction reperfusion following endovascular therapy for ischemic stroke is highly correlated with magnetic resonance imaging reperfusion, infarct growth, and clinical outcome.
DEFUSE 2研究表明,磁共振成像不匹配的患者对通过磁共振成像评估的组织再灌注有良好的临床反应。本研究报告血管内治疗结果,并将血管造影再灌注与临床和影像学结果相关联。
前瞻性纳入的缺血性卒中患者接受基线磁共振成像检查,并在发病12小时内开始血管内治疗。使用磁共振成像将患者分为目标不匹配组或无目标不匹配组。评估术前和术后血管造影以确定脑梗死溶栓评分。在第30天确定良好的临床反应,良好的功能结局定义为第90天改良Rankin量表评分为0 - 2分。
100例患者尝试进行血管内治疗。治疗结束时,23%的患者脑梗死溶栓评分为0 - 1分,31%为2A分,28%为2B分,18%为3分。更有利的脑梗死溶栓 - 再灌注评分与更高的磁共振成像再灌注相关(P<0.001)。脑梗死溶栓评分与30天良好临床反应(P = 0.041)和90天改良Rankin量表0 - 2分(P = 0.008)相关。这些相关性在目标不匹配患者的30天(P = 0.034)和90天(P = 0.003)时具有统计学意义。梗死灶扩大与目标不匹配患者较差的脑梗死溶栓评分密切相关(P<0.001)。与脑梗死溶栓2B - 3级患者相比,脑梗死溶栓2A级再灌注的患者磁共振成像再灌注较少(P = 0.004),90天时临床结局较差(P = 0.01)。
缺血性卒中血管内治疗后脑梗死溶栓再灌注与磁共振成像再灌注、梗死灶扩大和临床结局高度相关。